Biotech Values

[oc631]

I'm quite certain this was not the case and that the finding that PSI-938 was active against the 282T mutant, came as a good surprise.

It's clear they were advancing PSI-938 in the clinic to boost the resistance profile of PSI-7977. VRUS' early presentations on PSI-938's unique resistance to the 282T variant was a reason given for moving the program forward if my memory serves me (which it doesn't always).

Here's an old publication that stresses the point.






http://www.medscape.com/viewarticle/716161_5






PSI-938 was recently reported as a novel proprietary nucleotide purine analogue for the treatment of HCV.[44] PSI-938 confers a resistance profile that differs from the pyrimidine analogues R-7128 and PSI-7851 [PSI-7977] and is metabolized by a phosphorylation pathway that is distinct from both R-7128 and PSI-7851.[44] Together, R-7128, PSI-7851 and PSI-938 provide a multifaceted approach for combination therapy, wherein utilization of various combinations of C or U pyrimidine analogues with a purine analogue can be administered for maximized inhibition of viral replication. This strategy has proven to be very successful for the treatment of HIV infections (e.g. Truvada or Combivir).